| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1513098 |
| P8608 | Fatcat ID | release_ao7wiy3qhjbqphy5f4lzv7jkdu |
| P698 | PubMed publication ID | 27355533 |
| P50 | author | Olivier Hermine | Q28322530 |
| Cem Akin | Q42415677 | ||
| Hanneke C Kluin-Nelemans | Q50757186 | ||
| Peter Valent | Q56697676 | ||
| Karin Hartmann | Q71296764 | ||
| Elizabeth O. Hexner | Q85544163 | ||
| P2093 | author name string | Hans-Peter Horny | |
| Karl Sotlar | |||
| Jason Gotlib | |||
| Farrukh T Awan | |||
| Andreas Reiter | |||
| Tracy I George | |||
| Michael J Mauro | |||
| Eric J Stanek | |||
| David W Sternberg | |||
| Alice Huntsman Labed | |||
| Matthieu Villeneuve | |||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic mastocytosis | Q3851644 |
| P304 | page(s) | 2530-2541 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis | |
| P478 | volume | 374 |
| Q92228460 | A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases |
| Q88524714 | A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone |
| Q92727038 | A cross-sectional survey on patient safety culture among healthcare providers in the Upper East region of Ghana |
| Q38736625 | A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase. |
| Q92214144 | A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis |
| Q48380159 | A precision therapy against cancers driven by KIT/PDGFRA mutations. |
| Q91060595 | A useful add-on international prognostic score for mastocytosis? |
| Q91591513 | ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT |
| Q47113874 | Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy |
| Q33670596 | Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature |
| Q88599953 | Acute mast cell leukemia: A rare but highly aggressive hematopoietic neoplasm |
| Q34552564 | Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. |
| Q90701960 | Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia |
| Q48251471 | Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. |
| Q52838792 | Anaplastic mast cell sarcoma: a unique pathologic entity in mastocytosis. |
| Q64277635 | Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis |
| Q51322003 | CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. |
| Q54109246 | Case Report: Treatment of systemic mastocytosis with sunitinib. |
| Q41533457 | Case Report: Unusual Manifestation of KIT Negative Systemic Mastocytosis |
| Q92276375 | Clinical potential of midostaurin in advanced systemic mastocytosis |
| Q64277765 | Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML |
| Q57174064 | Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms |
| Q47161255 | Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. |
| Q92381105 | Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis |
| Q48513776 | Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis |
| Q48104415 | Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. |
| Q50044775 | Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. |
| Q91732120 | Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells |
| Q38661465 | Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial |
| Q57289107 | Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors |
| Q94552587 | European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis |
| Q53120787 | First new drug approval for AML in 15 years. |
| Q37706037 | Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis |
| Q47763014 | How we diagnose and treat systemic mastocytosis in adults |
| Q92887046 | Identification of a leukemia-initiating stem cell in human mast cell leukemia |
| Q99409940 | In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells |
| Q48505281 | Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia |
| Q92615039 | Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis |
| Q91060591 | International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study |
| Q49690038 | Invited Commentary: Mast Cell Activation |
| Q91011050 | KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis |
| Q55286285 | KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia. |
| Q92365302 | KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6 |
| Q38696593 | Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells |
| Q57176232 | Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives |
| Q90059535 | MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis |
| Q88282139 | Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome |
| Q99419174 | Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts |
| Q50122626 | Mastocytosis - pathogenesis, clinical manifestation and treatment |
| Q45069506 | Mastocytosis in Children |
| Q38777126 | Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts |
| Q50122660 | Mastozytose - Pathogenese, Klinik und Therapie |
| Q58554154 | Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models |
| Q64085683 | Midostaurin for acute myeloid leukaemia, mastocytosis, and mast cell leukaemia |
| Q38671401 | Midostaurin for the treatment of acute myeloid leukemia |
| Q38712298 | Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation |
| Q60949513 | Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis |
| Q47727992 | Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis |
| Q48212760 | Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". |
| Q47877035 | Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia |
| Q39371391 | Midostaurin: First Global Approval |
| Q47930594 | Midostaurin: a magic bullet that blocks mast cell expansion and activation |
| Q87899972 | Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis |
| Q90281835 | Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis |
| Q92879483 | Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches |
| Q92354973 | Novel approaches to treating advanced systemic mastocytosis |
| Q91936391 | Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia |
| Q59810100 | Preclinical human models and emerging therapeutics for advanced systemic mastocytosis |
| Q54160284 | Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. |
| Q89824485 | Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis |
| Q91709967 | Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions |
| Q92447847 | Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? |
| Q51368335 | Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. |
| Q91869797 | Recent advances in the understanding and therapeutic management of mastocytosis |
| Q48168851 | Routine abdominal ultrasonography has limited value in the care for patients with indolent systemic mastocytosis |
| Q49580473 | SOHO State-of-the-Art Update and Next Questions: MPN. |
| Q49376791 | Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy |
| Q42703964 | Systemic Mastocytosis in Association with Small Lymphocytic Lymphoma |
| Q97523448 | Systemic Mastocytosis: A Rare Cause of Diarrhea |
| Q94453146 | Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap |
| Q49742785 | Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review |
| Q39267824 | Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management |
| Q41061871 | Targeted Treatment Options in Mastocytosis |
| Q50035104 | The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. |
| Q64889470 | The Role of KIT Mutations in Anaphylaxis. |
| Q42234623 | The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm |
| Q64042239 | The new tool "" in advanced systemic mastocytosis |
| Q89449227 | Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells |
| Q89651597 | Turning liabilities into opportunities: Off-target based drug repurposing in cancer |
| Q99628484 | Update on CML-Like Disorders |
| Q61796830 | Validation of the Mayo alliance prognostic system for mastocytosis |
Search more.